<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709225</url>
  </required_header>
  <id_info>
    <org_study_id>18-341</org_study_id>
    <nct_id>NCT03709225</nct_id>
  </id_info>
  <brief_title>Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer</brief_title>
  <acronym>MAYA</acronym>
  <official_title>Exploring the Feasibility of a Mindfulness-Music Intervention to Reduce Anxiety and Stress in Adolescents and Young Adults Receiving Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating how well a music therapy program works to improve anxiety and stress
      in adolescents and young adults receiving cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study will test how well a music therapy program works to improve anxiety and
      stress in adolescents and young adults receiving cancer treatment. The program is designed to
      incorporate music-based meditation practices and music making activities (e.g., guitar,
      drums) to help promote relaxation during cancer treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adolescent and young adults recruited to participate in the music therapy program</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Feasibility of participant recruitment to the music intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of music therapy sessions attended by participants</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Feasibility of participant adherence to the music intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of outcome assessments completed by participants.</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Feasibility of participant adherence to outcome assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Satisfaction with Participation in Music Therapy Intervention as measured by the Adapted Acceptability E - Scale.</measure>
    <time_frame>End of treatment at 12 weeks</time_frame>
    <description>Each item of the Adapted Acceptability E - Scale is scored individually on a 1 - 5 scale, with higher scores representing greater acceptability and satisfaction with the music therapy intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic growth</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Post Traumatic Growth Inventory - Short Form score from enrollment to the end of treatment at 12 weeks. Total scores on the Post Traumatic Growth Inventory Short Form range from 0 - 50, with higher scores representing greater post-traumatic growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Perceived Stress Scale score from enrollment to the end of treatment at 12 weeks. The scale is scored from 0 - 40, with higher scores representing greater stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Interference: PROMIS</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference 4a score from enrollment to the end of treatment at 12 weeks. Total scores range from 41.6 - 75.6, with higher scores representing worse pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue 4a score from enrollment to the end of treatment at 12 weeks. Total scores range from 33.7 - 75.8, with higher scores representing worse fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with participation in social roles: PROMIS</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Satisfaction with Participation in Social Roles 4a score from enrollment to end of treatment at 12 weeks. Total scores range from 29 - 64.1, with higher scores representing worse satisfaction with participation in social roles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity: PROMIS</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in 0 - 10 numerical rating scale of average pain (included in Patient Reported Outcomes Measurement Information System (PROMIS) - 29 profile)) from enrollment to end of treatment at 12 weeks. Total scores range from 0 - 10, with higher scores representing worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Depression 4a score from enrollment to the end of treatment at 12 weeks. Total scores range from 41.0 - 79.4, with higher scores representing worse depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a score from enrollment to the end of treatment at 12 weeks. Total scores range from 40.3 - 81.6, with higher scores representing worse anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Function</measure>
    <time_frame>From enrollment to end of treatment at 12 weeks</time_frame>
    <description>Change in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function 4a score from enrollment to the end of treatment at 12 weeks. Total scores range from 22.9 - 56.9, with higher scores representing worse physical function.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Anxiety</condition>
  <condition>Oncology</condition>
  <condition>Stress</condition>
  <arm_group>
    <arm_group_label>Music-based meditation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:
Introduction to music therapy and mindfulness
Music-based meditation
Using personal music to shift energy, mood, and support relaxation
Mindfulness through active music making
Discuss bringing mindfulness to daily activities</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Music-based meditation</intervention_name>
    <description>The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment</description>
    <arm_group_label>Music-based meditation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15 - 39 years of age

          -  Have a diagnosis of any cancer

          -  Have begun treatment for cancer and plan to receive active cancer treatment (e.g.,
             radiation, chemotherapy, or oral chemotherapy) over the next eight weeks

          -  Signed informed consent/assent

          -  Willingness to participate in all study activities

          -  Speak/read English

        Exclusion Criteria:

          -  Prognosis &lt; 3 months,

          -  Self-report inability to physically interact with musical instruments (e.g., hold
             instruments)

          -  Documentation of significant hearing impairment (e.g., deaf).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Knoerl, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Knoerl, PhD, RN</last_name>
    <phone>617-632-6386</phone>
    <email>Robert_knoerl@DFCI.Harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Knoerl, MD</last_name>
      <phone>617-632-6386</phone>
      <email>robert_knoerl@DFCI.Harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Knoerl, PhD, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Robert Knoerl, PhD, RN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Music Therapy</keyword>
  <keyword>Oncology</keyword>
  <keyword>Adolescent and Young Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

